Will provide a defined period of regulatory exclusivity for qualifying botanical drug products while preserving existing FDA clinical trial, safety, and efficacy requirements.

The legislation would address barriers to late-stage development of botanical medicines by providing a defined period of regulatory exclusivity for qualifying products without exempting them from clinical trials or reducing FDA requirements

Boebert's press release says her Advancing Botanical Drug Development Act of 2026 would create regulatory exclusivity for qualifying botanical medicines while keeping FDA requirements in place.

REP. BOEBERT INTRODUCES ADVANCING BOTANICAL DRUG DEVELOPMENT ACT OF 2026 | Representative Lauren Boebert
primary · press_release · model gpt-5.5

unverified · Source version 65975 · locator unknown

"Ms. Boebert (for herself and Mr. Van Orden) introduced the following bill; which was referred to the Committee on Energy and Commerce"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official bill metadata shows Boebert introduced H.R. 10150 on August 27, 2026, and it was referred to committee, not enacted.

unresolved same_term A for effort

H.R. 10150 (IH) - Advancing Botanical Drug Development Act of 2026 - BILLS-119hr10150ih | Content Details | GovInfo
primary · model gpt-5.5 · confidence 96%

unverified · Source version 65977 · locator unknown

"shall be entitled to a 12-year period"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The introduced bill text would create a defined exclusivity period for qualifying botanical drugs if enacted.

unresolved same_term A for effort

GovInfo Bill Text: H.R. 10150 Introduced in House
secondary · model gpt-5.5 · confidence 95%

unverified · Source version 65977 · locator unknown

"same standards of safety and effectiveness applicable to other drugs regulated by the FDA"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The introduced bill text preserves FDA safety and effectiveness standards, matching the clinical-safety-efficacy condition in the commitment.

unresolved same_term A for effort

GovInfo Bill Text: H.R. 10150 Introduced in House
secondary · model gpt-5.5 · confidence 94%

unverified · Source version 65979 · locator unknown

"Submit either electronic or written comments, data, or information by November 3, 2026."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): FDA opened an information-gathering docket during the lookback period, but this is not the statutory exclusivity promised by the claim.

unresolved unknown

Federal Register :: Advancing Development of Botanical Drug Products; Request for Information
secondary · model gpt-5.5 · confidence 86%